Theravance Biopharma (TBPH) Announces Receipt of Russian Marketing ...
VIBATIV is a bactericidal, once-daily antibiotic with in vitro potency and a dual mechanism of action against Gram-positive bacteria, including difficult-to-treat pathogens such as MRSA. VIBATIV will be marketed and sold in Russia by ... bacterial cell ...
StreetInsider.com - Tue, 30 Jun 2015 05:10

Theravance Biopharma Announces Marketing Authorization for VIBATIV(R ...
SYS-CON Media (press release) - Tue, 30 Jun 2015 05:27

Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin™ for ...
SAN JOSE, Calif., June 30, 2015 /PRNewswire/ -- Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration ...
PR Newswire (press release) - Tue, 30 Jun 2015 08:56



Acid-reducing drugs could increase risk of bacterial infection in children
They note that the gastric flora of children taking H2RAs or PPIs have greater numbers of Streptococcus and other gram-positive bacteria compared with children who do not take acid suppression medication. Report co-author Daniel Freedberg said: “The ...
The Pharmaceutical Journal - Fri, 26 Jun 2015 07:25

Basilea's novel antibiotic reaches UK market
It is a broad-spectrum antibiotic and can be used to treat infections caused both Gram- positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas species. Treatment failure rates in pneumonia, ...
PMLiVE - Mon, 29 Jun 2015 02:33



Tackling superbugs, 'crisis of this generation,' report says
Antibiotic resistance and its dangers have been decades in the making as infectious “gram-negative” and “gram-positivebacterial strains have evolved. Gram-negative bacteria have been problems as hospital-acquired infections that can cause secondary ...
Healthcare Finance News - Tue, 23 Jun 2015 07:48

Cantor Fitzgerald Rating Update on Tetraphase Pharmaceuticals, Inc. (NASDAQ ...
... multi-drug resistant Gram-negative infections. . The Companys frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is ...
Money Flow Index - Mon, 29 Jun 2015 04:26

China Pioneer Pharma Offers Free NeutroPhase to Victims Suffered Burns in the ...
This product uses the unique mechanism of HOCl to kill bacterium (Gram-positive bacteria and gram-negative bacteria), fungi and viruses quickly to control infection and neutralize bacterial toxins. It can be widely used in a variety of acute and ...
ACN Newswire (press release) - Mon, 29 Jun 2015 06:18

Biotech Stocks in News - Paratek Pharmaceuticals Inc (NASDAQ:PRTK ...
The company, on June 23, 2015, reported the dosing of the first patient in its Phase 3 clinical trial of its lead drug candidate, omadacycline, for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). This global Phase 3 study ...
Wall Street Observer - Mon, 29 Jun 2015 02:56


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014